Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$11.7 - $14.98 $210,284 - $269,235
-17,973 Reduced 58.56%
12,720 $158,000
Q4 2023

Jan 12, 2024

SELL
$13.09 - $14.98 $584,010 - $668,332
-44,615 Reduced 59.24%
30,693 $429,000
Q3 2023

Oct 13, 2023

BUY
$12.64 - $14.99 $951,893 - $1.13 Million
75,308 New
75,308 $1.11 Million
Q1 2023

Apr 28, 2023

BUY
$9.44 - $11.88 $683,484 - $860,147
72,403 New
72,403 $710,000
Q3 2022

Oct 31, 2022

SELL
$9.93 - $17.44 $38,786 - $68,120
-3,906 Reduced 14.09%
23,823 $249,000
Q2 2022

Jul 29, 2022

BUY
$7.45 - $12.83 $206,581 - $355,763
27,729 New
27,729 $349,000
Q1 2022

Apr 29, 2022

SELL
$9.75 - $14.44 $325,669 - $482,324
-33,402 Closed
0 $0
Q4 2021

Feb 07, 2022

SELL
$13.17 - $20.94 $160,976 - $255,949
-12,223 Reduced 26.79%
33,402 $470,000
Q3 2021

Nov 01, 2021

BUY
$9.16 - $19.83 $417,925 - $904,743
45,625 New
45,625 $876,000
Q2 2021

Aug 12, 2021

SELL
$7.25 - $10.99 $148,487 - $225,086
-20,481 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$4.57 - $11.18 $39,078 - $95,600
8,551 Added 71.68%
20,481 $201,000
Q4 2020

Feb 04, 2021

SELL
$3.73 - $5.6 $493,740 - $741,272
-132,370 Reduced 91.73%
11,930 $53,000
Q3 2020

Nov 09, 2020

BUY
$4.32 - $11.7 $623,376 - $1.69 Million
144,300 New
144,300 $623,000
Q2 2020

Jul 20, 2020

SELL
$2.94 - $9.1 $49,706 - $153,853
-16,907 Closed
0 $0
Q1 2020

Apr 30, 2020

BUY
$2.27 - $6.2 $38,378 - $104,823
16,907 New
16,907 $60,000
Q3 2018

Nov 06, 2018

SELL
$11.85 - $16.0 $107,076 - $144,576
-9,036 Closed
0 $0
Q2 2018

Aug 07, 2018

BUY
$15.15 - $20.75 $50,146 - $68,682
3,310 Added 57.81%
9,036 $138,000
Q1 2018

May 03, 2018

SELL
$14.65 - $19.9 $42,353 - $57,530
-2,891 Reduced 33.55%
5,726 $114,000
Q4 2017

Jan 24, 2018

SELL
$17.3 - $24.08 $81,604 - $113,585
-4,717 Reduced 35.38%
8,617 $161,000
Q3 2017

Nov 07, 2017

BUY
$15.2 - $21.5 $202,676 - $286,681
13,334
13,334 $287,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.6B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.